GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bioventix PLC (LSE:BVXP) » Definitions » ROCE %

Bioventix (LSE:BVXP) ROCE %

: 87.72% (As of Dec. 2023)
View and export this data going back to 2014. Start your Free Trial

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Bioventix's annualized ROCE % for the quarter that ended in Dec. 2023 was 87.72%.


Bioventix ROCE % Historical Data

The historical data trend for Bioventix's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioventix Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
ROCE %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 64.22 68.13 66.35 78.08 84.63

Bioventix Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
ROCE % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 65.45 105.80 80.09 100.29 87.72

Bioventix ROCE % Calculation

Bioventix's annualized ROCE % for the fiscal year that ended in Jun. 2023 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Jun. 2023 )  (A: Jun. 2022 )(A: Jun. 2023 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Jun. 2023 )  (A: Jun. 2022 )(A: Jun. 2023 )
=10.134/( ( (13.118 - 1.252) + (13.282 - 1.2) )/ 2 )
=10.134/( (11.866+12.082)/ 2 )
=10.134/11.974
=84.63 %

Bioventix's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2023 )  (Q: Jun. 2023 )(Q: Dec. 2023 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2023 )  (Q: Jun. 2023 )(Q: Dec. 2023 )
=10.318/( ( (13.282 - 1.2) + (13.149 - 1.707) )/ 2 )
=10.318/( ( 12.082 + 11.442 )/ 2 )
=10.318/11.762
=87.72 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bioventix  (LSE:BVXP) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.


Bioventix ROCE % Related Terms

Thank you for viewing the detailed overview of Bioventix's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Bioventix (LSE:BVXP) Business Description

Traded in Other Exchanges
Address
East Street, 7 Romans Business Park, Farnham, Surrey, GBR, GU9 7SX
Bioventix PLC is a biotechnology company based in the United Kingdom. It specializes in the creation and supply of high-affinity sheep monoclonal antibodies and clinical diagnostics and drug abuse testing. The company's portfolio of products includes drugs that are applicable in the areas of cardiology, fertility, infectious diseases, Thyroid, and vitamin D disorder among others.

Bioventix (LSE:BVXP) Headlines

No Headlines